A review on newly approved PARP inhibitors: Talazoparib and Olaparib
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
第一著者: | Karim, Azrin |
---|---|
その他の著者: | Islam, Farzana |
フォーマット: | Project report |
言語: | English |
出版事項: |
Brac University
2024
|
主題: | |
オンライン・アクセス: | http://hdl.handle.net/10361/24372 |
類似資料
-
A review on potential of PARP inhibitors in the treatment of prostate cancer
著者:: Islam, Saidul
出版事項: (2022) -
Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
著者:: Ahmed, Nafisa
出版事項: (2023) -
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
著者:: Meem, Manila
出版事項: (2023) -
Mutation in DNA polymerase γ: mitochondrial disorders
著者:: Hossain, Sadman Sanjid
出版事項: (2023) -
RIPK pathway, as a potential target, for cancer treatment - a review
著者:: Jahan, Nusrat
出版事項: (2024)